US EditionArcus’ Quemliclustat Earns Orphan Drug Designation As Phase III Pancreatic Cancer Trial Advances - Data Intelligence
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Arcus’ Quemliclustat Earns Orphan Drug Designation As Phase III Pancreatic Cancer Trial Advances - Data Intelligence
Image Credit: © Matthieu – stock.adobe.com Key takeaways Orphan drug designation for quemliclustat highlights regulatory momentum and unmet need in pancreatic cancer treatment development. PRISM-1 Phase III trial design reflects gold-standard methodologies (randomized, double-blind, placebo-controlled) with a large global patient population. ARC-8 survival data and use of a Synthetic Control Arm (SCA) underscore the growing role of adaptive an…
Quemliclustat: Designation FDA Orphan against Pancreas Cancer Pancreas Cancer: New Encouraged with the Quemliclustat – A Medical Perceived? Urgent News:... The post Quemliclustat: Designation FDA Orphan against Pancreas Cancer appeared first on World News.
While life expectancy has more than doubled in the few years since diagnosis, the prognosis remains grim. Promising innovations are expected to better control the progression of the disease.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
